Do not use in pregnant or lactating females.

Do not use in cats suffering from systemic disease such as primary liver disease or diabetes mellitus.

Do not use in cats showing signs of autoimmune disease.

Do not use in animals with disorders of white blood cells, such as neutropenia and lymphopenia.

Do not use in animals with platelet disorders and coagulopathies (particularly thrombocytopenia).

Do not use in cats with hypersensitivity to Thiamazole or the excipient, Polyethylene Glycol.

Concurrent treatment with Phenobarbital may reduce the clinical efficacy of Thiamazole.

Concurrent treatment with Benzimidazole wormers is known to reduce the hepatic oxidation of these actives and may lead to increases in circulating levels.

Thiamazole is immunomodulatory therefore this should be taken into account when considering vaccination programmes.

In a clinical field study approximately 20 % of the cats experienced some form of adverse reaction, most frequently when the product was used for long-term control of hyperthyroidism. In many cases symptoms may be mild and transitory and not a reason for withdrawal of treatment. The more serious effects are mainly reversible when medication is stopped. At doses of up to 10-15 mg the clinical side effects were vomiting, inappetance/anorexia, lethargy, severe pruritus and excoriations of the head and neck, bleeding diathesis and icterus associated with hepatopathy, and haematological abnormalities (eosinophilia, lymphocytosis, neutropenia, lymphopenia, slight leucopenia, agranulocytosis, thrombocytopenia or haemolytic anaemia). These side effects resolved within 7-45 days after cessation of Thiamazole therapy.

Haematology must be monitored due to risk of leucopenia or haemolytic anaemia.

Any animal that suddenly appears unwell during therapy, particularly if they are febrile, should have a blood sample taken for routine haematology and biochemistry.

Neutropenic animals (neutrophil counts <2.5 x 109/l) should be treated with prophylactic bactericidal antibacterial drugs and supportive therapy.

Immunological side effects (anaemia, thrombocytopenia, serum anti-nuclear antibodies) can occur. Treatment should be stopped immediately and alternative therapy considered following a suitable period for recovery.

Use of the product in cats with renal dysfunction should be subject to careful risk : benefit assessment by the clinician.

Due to the effect Thiamazole can have on the glomerular filtration rate, the effect of therapy on renal function should be monitored closely as deterioration of an underlying condition may occur.

As Thiamazole can cause an increase in haemoconcentration, cats should always have access to drinking water.

If overdosage occurs, stop treatment and give symptomatic and supportive care.

Following long-term treatment with Thiamazole in rodents, an increased risk of neoplasia in the thyroid gland has been shown to occur, but no evidence is available in cats.

Operator warnings: Wash hands after use.

Wash hands with soap and water after handling litter used by treated animals.

Do not eat, drink or smoke while handling the tablet or used litter.

Do not handle this product if you are allergic to hyperthyroidism inhibitors.

Do not break or crush tablets.

As Thiamazole is a suspected human teratogen, women of child-bearing age should wear gloves when handling litter of treated cats.

In the event of accidental ingestion, seek medical advice immediately and show the package insert or the label to the physician.

Thiamazole may cause vomiting, epigastric distress, headache, fever, arthralgia, pruritus and pancytopenia. Treatment is symptomatic.

General precautions: For animal treatment only.